title: High-dose therapy and autologous stem-cell transplantation can improve event-free survival for indolent lymphoma: a study using patients as their own controls.
abstract: BACKGROUND
  High-dose therapy (HDT) and autologous stem-cell transplantation (ASCT) remain controversial for indolent lymphoma patients.
  
  
  METHODS
  The study was designed to evaluate the benefit of this strategy by retrospectively comparing for each patient the event-free survival (EFS) after ASCT with the duration of the disease phase just before the phase including ASCT (ie, the last qualifying phase, LQP).
  
  
  RESULTS
  A total of 109 indolent lymphoma (mostly follicular lymphoma) patients were treated with HDT and ASCT. Before ASCT, patients experienced a median of 2 disease phases (range, 1-4). After a median 5-year follow-up from ASCT, overall survival was 67% and EFS was 43%. When each of the 92 patients experiencing recurrence was taken as her/his own control, EFS was longer after ASCT than the duration of LQP (62%, P < .01). During LQP, 86 patients (93%) experienced recurrence in less than 5 years, compared with only 58 (63%) who experienced recurrence in the 5 years after ASCT (P < .01).
  
  
  CONCLUSIONS
  HDT and ASCT can significantly increase EFS in comparison with the duration of the LQP for indolent lymphoma patients and can change disease course. This methodology has been found useful for evaluating new strategies, especially with monoclonal antibodies.
authors.affiliation: Institut Universitaire d'Hématologie, INSERM U728, Hôpital Saint-Louis, Paris, France. stephane.vignot@sls.aphp.fr
authors.forename: Stéphane
authors.initials: S
authors.lastname: Vignot
authors.forename: Nicolas
authors.initials: N
authors.lastname: Mounier
authors.forename: Jérôme
authors.initials: J
authors.lastname: Larghero
authors.forename: Pauline
authors.initials: P
authors.lastname: Brice
authors.forename: Laurent
authors.initials: L
authors.lastname: Quero
authors.forename: Cédric
authors.initials: C
authors.lastname: de Bazelaire
authors.forename: Marjan
authors.initials: M
authors.lastname: Ertault
authors.forename: Josette
authors.initials: J
authors.lastname: Brière
authors.forename: Isabelle
authors.initials: I
authors.lastname: Madelaine
authors.forename: Christian
authors.initials: C
authors.lastname: Gisselbrecht
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000401:mortality / Q000628:therapy*; D008224:Lymphoma, Follicular / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D033581:Stem Cell Transplantation / Q000379:methods; D014182:Transplantation, Autologous
chemical_list: D000970:Antineoplastic Agents